Carcinoma of Unknown Primary Clinical Trial
Official title:
An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
This is an open-label, multinational, multicenter, randomized, comparative efficacy and safety study in previously untreated patients with carcinoma of unknown primary. Patients meeting inclusion and exclusion criteria will be randomized to treatment in Arm A (BelCaP) or Arm B (CaP). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00003943 -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
|
Phase 2 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Recruiting |
NCT02590055 -
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
|
Phase 2 | |
Completed |
NCT00002507 -
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Recruiting |
NCT03740503 -
Genomic Investigation of Unusual Responders
|
||
Terminated |
NCT00148135 -
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
|
Phase 2 | |
Completed |
NCT00003582 -
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00014456 -
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
Completed |
NCT00357630 -
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
|
Phase 2 | |
Active, not recruiting |
NCT01366144 -
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT00004922 -
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00119314 -
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00047125 -
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
|
Phase 3 | |
Completed |
NCT00003657 -
High-dose ICE With Amifostine
|
Phase 2 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Recruiting |
NCT02764216 -
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
|
Phase 2 | |
Completed |
NCT00388024 -
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
|
N/A | |
Completed |
NCT00066781 -
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
|
Phase 2 |